Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study

Natássia Cristina Carboni Truzzi1, Leonardo Santos Hoff2, Isabela Bruna Pires Borges1, Fernando Henrique Carlos de Souza3 and Samuel Katsuyuki Shinjo1*

Abstract

Background: Currently, only a few retrospective cohort or cross-sectional studies have described the general characteristics of Brazilian patients with classical dermatomyositis (DM). In contrast, we aimed to longitudinally assess a large sample of these patients, and several myositis autoantibodies.

Methods: This single-center longitudinal study included 91 Brazilian adults with defined DM (EULAR/ACR 2017) who underwent follow-up appointments in our tertiary center from 2012 to 2021. Myositis autoantibody analysis was performed using a commercial kit.

Results: The mean age of the patients was 47.3 ± 15.4 years, with a predominance of female (67.0%) and White (81.3%) patients. As an initial treatment, 76.9% of the patients received methylprednisolone pulse therapy, 59.3% received intravenous immunoglobulin, and 54.9% received both drugs. The median follow-up duration was 44 months (interquartile 17–67) months. There were 92 severe episodes of infection, and neoplasms were identified in 20 patients (22.0%). Hypertension was identified in 46.2% of patients, whereas diabetes mellitus and myocardial infarction occurred in 19.8% and 4.4%, respectively. Nine patients died during the follow-up. At the last visit, one-third of the patients had disease activity, half had a complete clinical response, and one-fifth were in disease remission. In a univariate logistic regression, anti-aminoacyl-tRNA synthetase antibodies (n = 13) were associated with interstitial lung disease, “mechanic’s hands”, and anti-Ro-52, and had an inverse association with “V”-neck and “shawl” signs. Anti-MDA-5 (n = 10) were associated with male gender, digital ulcers, vasculitis, arthritis, anti-Ro-52, and active disease. Anti-Ro-52 (n = 26) were associated with “mechanic’s hands”, arthritis, interstitial lung disease, anti-tRNA synthetases, and anti-MDA-5. No association was found for anti-Mi-2 (n = 10).

Conclusions: This study shows the general profile of a significant sample of Brazilian patients with DM as well as the association of some antibodies with clinical and laboratory manifestations of this myositis.

Keywords: Dermatomyositis, Autoantibodies, Longitudinal study, Outcome, Treatment

Introduction

Dermatomyositis (DM) is a systemic autoimmune myopathy characterized by skin involvement and predominant proximal limb muscle weakness [1]. Concerning cutaneous manifestations, patients with DM may show...
classic signs, such as heliotrope and papules/Gottron's sign, whereas secondary cutaneous disorders include facial rash, “V-neck sign,” “shawl sign,” ulcers, vasculitis, calcinosis, and others. Moreover, manifestations in the joints, lungs, heart, and gastrointestinal tract may also be present [2, 3].

Myositis autoantibodies have been detected in up to 60% of patients with inflammatory myopathies. Those that are most relevant for DM are anti-Jo-1, anti-Mi-2, anti-MDA-5, anti-TIF1-γ, anti-SAE, and anti-NXP-2 [4, 5]. Detection of these autoantibodies allows for better characterization of DM's phenotypic pattern of DM and establishes associations with clinical manifestations and prognosis [6–21]. The autoantibody profile and associations with DM manifestations vary according to the geographic area.

Only a few epidemiological studies of patients with DM have been conducted [6–23]. The majority of these studies were limited to cross-sectional [7, 9, 11, 16, 17] or retrospective studies [6, 12, 14, 15, 18, 20, 22], with a small number of patients with DM [13, 18, 23] or heterogeneous cohorts, consisting of patients with probable or possible DM diagnosis [9, 11, 13, 18, 23]. Furthermore, only five studies analyzing myositis-specific autoantibodies have been performed in a Brazilian population with DM [6, 7, 14, 15, 17].

Therefore, the present study aimed to longitudinally evaluate the clinical, laboratory, and evolutive profiles of a significant sample of Brazilian patients with a definitive DM diagnosis, as well as to analyze possible associations between myositis-specific autoantibodies and myositis-associated autoantibodies with the characteristics of this disease.

**Patients and methods**

This was a longitudinal, single-center study. Adult patients with classic DM were assessed at the Inflammatory Myopathies Clinic of our tertiary service between January 2012 and July 2021. This study was approved by the local research ethics committee (CAAE 68523717.1.0000.0068) and all participants signed the term free and informed consent.

Only patients at least 18 years old and with definite DM per the 2017 European League Against Rheumatism/American College of Rheumatology (EULAR / ACR) criteria classification were included [24]. Patients with clinically amyopathic DM [25], overlap syndromes, and other inflammatory myopathies were excluded.

Demographic features, treatment, clinical, and laboratory data were obtained at the first and last medical visits, and any missing information was retrieved from the patient’s files.

We collected demographic, clinical, laboratory, disease activity status, and therapeutic information using pre-standardized and parameterized information.

- **Demographics:** Age at disease diagnosis, sex, and ethnicity.
- **Clinical manifestations:** symptoms onset, disease duration, outpatient follow-up time, cutaneous involvement (heliotrope rash, Gottron’s papules/sign, facial rash, “mechanic’s hand,” ulcers, calcinosis, vasculitis, “V-neck sign,” “shawl sign,” and periungual hyperemia), Raynaud’s phenomenon, systemic manifestations (dysphagia, arthritis, dysphonia, dyspnea, and weight loss); limb muscle strength graded according to the Medical Research Council (MRC) classification [26].
- **Complementary examinations:** serum levels of muscle enzymes in blood samples [creatine phosphokinase (CPK), aminotransferase alanine (ALT), aminotransferase aspartate (AST), and lactic dehydrogenase (LDH)], electromyography tests revealing predominance of proximal myopathy with no neurological pattern, muscle biopsy of bicep arm or muscle vastus lateralis muscle with the presence of inflammatory infiltrate in the perimysial and perivascular area, and/or perifascicular atrophy. Changes in high-resolution computed tomography images of the lung: incipient interstitial lung disease (ILD), ground-glass opacities, and pulmonary fibrosis in both lung bases.
- **Outcomes:** Diagnosis of neoplasms, severe infections (defined as an infection that required parenteral therapy or tuberculosis), and deaths.
- **Disease activity status on the last medical appointment:** was defined according to the international consensus guidelines for trials of myositis therapies (proposed by the International Myositis Assessment and Clinical Studies Group - IMACS) [27] as clinical remission (no evidence of disease activity for at least six months without DM treatment), complete clinical response (no evidence of disease activity for at least six months while still receiving myositis therapy), or disease relapse: recurrence of clinical (muscle or skin manifestations) and/or laboratory findings (elevated creatine phosphokinase or aldolase) with no explanation other than disease activity.
- **Comorbidities:** systemic arterial hypertension, type 2 diabetes mellitus, acute myocardial infarction.
- **Habits and addictions:** current and previous smoking and/or alcohol use disorder.
- **Drug treatment:** initial treatment (received in the first year after diagnosis) with intravenous methylprednisolone (IVMP) or intravenous immunoglobulin...
(IVIg), current dose of glucocorticoids, immunosuppressive, immunomodulatory, or immunobiological drugs.

An analysis of the profile of myositis-specific (specific for myositis) and myositis-associated (associated with myositis and other rheumatological diseases) autoantibodies was performed in the serum samples of these patients, collected during the follow-up, and stored at −20 °C. Autoantibodies (Jo-1, OJ, EJ, PL-7, PL-12, PM/Scl75, PM/Scl100, Ku, SRP, Mi-2α, Mi-β, Ro-52, MDA-5, TIF-1γ, SAE, and NXP-2) were analyzed using an immunoblotting commercial kit (DL 1530-1601-4G, Euroimmun, Lübeck, Germany).

Statistical analysis. The Shapiro–Wilk test was used to assess the normality of the distribution of continuous variables. Results are presented as mean ± standard deviation or median (interquartile range [IQR] 25–75%) for continuous parameters and number (%) for categorical variables. To compare the differences between patients with and without myositis-specific autoantibodies, we used the Student’s t-test for continuous variables with normal distribution and the Mann–Whitney U test for continuous variables with non-normal distribution. For categorical variables, differences were calculated using the chi-squared test; Fisher’s exact test was used when >20% of cells had an expected count of less than 5 in a 2 × 2 contingency table. We further explored the association between clinical, imaging, and laboratory features and the main autoantibodies using a univariate binary logistic regression to calculate odds ratios (OR) with a 95% confidence interval (CI). A P value < 0.05 was considered statistically significant. Analyses were performed using IBM SPSS Statistics for Windows (version 24.0; IBM Corp, Armonk, NY, USA).

**Results**

Of the 112 patients with a defined DM diagnosis who were initially admitted, 21 were excluded (Fig. 1); thus, information was collected from 91 patients, of whom 74 had the autoantibodies analyzed. According to the demographic profile, the mean age at DM diagnosis was 47.3 ± 15.4 years, with a predominance of white females (Table 1).

The main cutaneous manifestation was Gotttron’s sign or papules (96.7%), followed by a heliotrope rash (86.8%) and “V”-neck sign (78%). At the onset of DM diagnosis, 90% of the patients had muscle weakness with MRC grade IV or III. Systematic manifestations, such as dysphagia, arthritis, and lung involvement were observed in 73.6%, 33.0%, and 37.4%, respectively. Maximum levels of CPK (3121 U/L), AST (32 U/L), ALT (98 U/L), and LDH (904 U/L) were detected in laboratory exams. The full description of general characteristics is summarized in Table 1. The median follow-up time was 44 months (range 17–67 months) (Table 2).

Concerning the initial medical treatment, 76.9% of the patients received IVMP, 59.3% received IVIg, and 54.9% received both medications. During follow-up, patients received different types of immunosuppressants, immunomodulators, or immunobiological, such as methotrexate (23.1%), azathioprine (13.2%), mycophenolate mofetil (13.2%), and leflunomide (8.8%); one-third of the patients received rituximab (Table 2).

Patients’ attendance at regular follow-up was 83.3% (Table 2). Based on the last medical appointment, one-third of the patients had disease relapse, half had a complete clinical response, and one-fifth were in remission. Only one-third of the patients were still on glucocorticoids, with a median dose of 0.0 (IQR 0.0–7.5) mg/day.

There were 92 episodes of severe infections; during the follow-up, the most frequent was community-acquired pneumonia, followed by herpes zoster, tuberculosis, and COVID-19. Twenty patients (22%) developed neoplasms, with the female breasts as the main primary site. Nine patients died of different causes, ranging from infectious (2.2%) to neoplastic processes (4.4%) (Table 3).

Systemic arterial hypertension was identified in 46.2% of the patients, while diabetes mellitus and acute myocardial infarction were present in 19.8% and 4.4% of the patients, respectively. Former and current smokers were observed in 12.2% and 9.9% of patients, respectively, while former alcohol use disorder was observed in 8.8%; current alcohol use disorder was present in only one patient.

The clinical, imaging, and laboratory features among the main autoantibodies profiles are shown in Table 3. A univariate binary logistic regression (Table 4) has shown
that heliotrope rash and Raynaud’s phenomenon were associated with positive antinuclear antibodies (ANA) (OR = 3.63, 95%CI 1.04–12.64, P = 0.043, and OR = 2.58, 95%CI 1.05–6.39, P = 0.040, respectively). “V”-neck sign (OR = 0.07, 95%CI 0.02–0.28, P < 0.001) and “shawl” sign (OR = 0.22, 95%CI 0.06–0.79, P = 0.021) had an inverse association with anti-tRNA synthetases, while “mechanics’ hands” (OR = 5.30, 95%CI 1.49–18.90, P = 0.010), ILD (OR = 5.38, 95%CI 1.47–19.72, P = 0.011), and anti-Ro-52 antibodies (OR = 3.82, 95%CI 1.10–13.28, P = 0.035) had a positive association with anti-tRNA synthetases. Male gender (OR = 4.90, 95%CI 1.22–19.69, P = 0.025), digital ulcers (OR = 9.67, 95%CI 2.16–43.22, P = 0.003), vasculitis (OR = 12.00, 95%CI 2.31–62.46, p = 0.003), arthritis (OR = 4.78, 95%CI 1.12–20.36, P = 0.034), anti-Ro-52 (OR = 5.53, 95%CI 1.29–23.68, P = 0.021), and active disease (OR = 6.11, 95%CI 1.47–25.43, P = 0.013) were associated with anti-MDA-5 antibodies. “Mechanics’ hands” (OR = 4.30, 95%CI 1.41–13.13, P = 0.011), arthritis (OR = 3.67, 95%CI 1.34–10.03, P = 0.011), RP-ILD

Table 1 General characteristics of 91 adult patients with defined dermatomyositis

| Characteristics                              | N = 91            |
|----------------------------------------------|-------------------|
| Age at disease diagnosis (years)             | 47.3 ± 15.4       |
| Female gender                               | 61 (67.0)         |
| White ethnicity                             | 74 (81.3)         |
| Constitutional symptoms at baseline         | 81 (89.0)         |
| Gottron’s sign/papules                       | 87 (96.7)         |
| Heliotrope rash                              | 79 (86.8)         |
| “V”-neck sign                                | 71 (78.0)         |
| “Shawl” sign                                 | 56 (61.5)         |
| Raynaud’s phenomenon                         | 55 (60.4)         |
| Vasculitis                                   | 26 (28.6)         |
| “Mechanics’ hands”                           | 20 (21.0)         |
| Skin ulcers                                  | 15 (16.5)         |
| Calciosis                                    | 4 (4.4)           |
| Muscle strength (MRC)                        |                   |
| Upper limbs                                  |                   |
| V degree                                     | 1 (1.1)           |
| IV degree                                    | 61 (67.0)         |
| III degree                                   | 23 (25.3)         |
| II degree                                    | 6 (6.6)           |
| Lower limbs                                  |                   |
| V degree                                     | 5 (5.5)           |
| IV degree                                    | 56 (61.6)         |
| III degree                                   | 24 (26.4)         |
| II degree                                    | 6 (6.6)           |
| Dysphagia                                    | 67 (73.6)         |
| Arthritis                                    | 30 (33.0)         |
| Lung involvement                             | 34 (37.4)         |
| Interstitial pneumopathy                     | 32 (35.2)         |
| Ground glass opacities                       | 12 (13.2)         |
| Pneumomeadiastinum                           | 1 (1.1)           |
| Maximum levels of muscle enzymes             |                   |
| Creatine phosphokinase (U/L)                 | 812 (177–3121)    |
| Aspartate aminotransferase (U/L)             | 62 (26–32)        |
| Alanine aminotransferase (U/L)               | 43 (21–98)        |
| Lactic dehydrogenase (U/L)                   | 531 (248–904)     |
| Antinuclear antibodies                       |                   |
| Myostis-specific autoantibodies (N = 74)     |                   |
| Anti-Mi-2                                    | 10 (11.0)         |
| Anti-Jo-1                                    | 10 (11.0)         |
| Anti-MDA-5                                   | 10 (11.0)         |
| Anti-TIF-1y                                  | 7 (7.7)           |
| Anti-SAE                                     | 6 (6.6)           |
| Anti-NXP-2                                   | 5 (5.5)           |
| Myostis-associated autoantibodies (N = 74)   |                   |
| Anti-Ro-52                                   | 26 (28.6)         |
| Anti-PmScl 75                                | 3 (3.3)           |
| Anti-SRP                                     | 1 (1.1)           |
| Anti-OJ, -EI, -PL-7, -PL-12, -Ku             | 3 (3.3)           |

Data are expressed as mean ± standard deviation, median (IQR 25th–75th), or percentage (%)

Table 2 Treatment characteristics and follow-up of 91 patients with dermatomyositis

| Characteristics                              | N = 91            |
|----------------------------------------------|-------------------|
| Current follow-up                           | 75 (83.3)         |
| Duration of follow-up (months)               | 44 (17–67)        |
| Disease status at the last medical evaluation|                   |
| Active disease (clinical relapse)            | 30 (33.0)         |
| Complete clinical response                   | 44 (48.4)         |
| Disease remission                           | 17 (18.7)         |
| Treatment                                    |                   |
| Previous IVMP pulse therapy                  | 70 (76.9)         |
| Previous IVIg                                | 54 (59.3)         |
| Previous IVIg + IVMP pulse therapy           | 50 (54.9)         |
| No IVMP or IVIg                             | 14 (15.4)         |
| Current treatment                           |                   |
| Glucocorticoid                              |                   |
| Current use                                  | 30 (33.0)         |
| Current dose (prednisone equivalent), mg/day  | 0.0 (0.0–7.5)     |
| Immunosuppressive/immunomodulatory/immunobiological |            |
| Methotrexate                                 | 21 (23.1)         |
| Azathioprine                                 | 12 (13.2)         |
| Myophenolate mofetil                         | 12 (13.2)         |
| Leflunomide                                  | 8 (8.8)           |
| Cyclosporine                                 | 3 (3.3)           |
| Cyclophosphamide                             | 1 (1.1)           |
| Rituximab                                    | 30 (33.0)         |

IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone

Data are expressed as mean ± standard deviation, median (IQR 25th–75th), or percentage (%).
Table 3  Outcomes during follow-up

| Outcomes                                | N = 91 |
|-----------------------------------------|--------|
| Cancer                                   | 20 (22.0) |
| Breast                                  | 8 (8.8) |
| Stomach                                 | 4 (4.4) |
| Lung                                    | 2 (2.2) |
| Cervical                                | 1 (1.1) |
| Uterus                                  | 1 (1.1) |
| Melanoma                                | 1 (1.1) |
| Thyroid                                 | 1 (1.1) |
| Non-Hodgkin's lymphoma                  | 2 (2.2) |
| Nasopharyngeal                          | 1 (1.1) |
| Gastrointestinal stromal tumors         | 1 (1.1) |
| Severe infections                       | 48 (52.7) |
| Pneumonia                               | 15 (16.5) |
| Herpes-zoster                           | 11 (12.1) |
| Tuberculosis                            | 5 (5.5) |
| COVID-19                                | 3 (3.3) |
| Other causes                            | 58 (63.7) |
| Total episodes of infections            | 92 |
| Death                                   | 9 (9.9) |
| Infections                              | 2 (2.2) |
| Neoplasia                               | 4 (4.4) |
| Other causes                            | 3 (3.3) |

Data expressed as a percentage (%)

(OR = 3.82, 95%CI 1.10–13.28, P = 0.035), anti-tRNA synthetases (OR = 3.82, 95%CI 1.10–13.28, P = 0.035), and anti-MDA-5 (OR = 5.53, 95%CI 1.29–23.68, P = 0.021) were associated with anti-Ro-52 antibodies (Table 5).

Discussion
This study evaluated the demographic, clinical, laboratory, therapeutic, and outcome characteristics of patients with DM, during a median follow-up time of 44 months. The frequency of clinical visits could not be established, since those were individualized based on the severity of the clinical condition, disease duration, presence of extramuscular characteristics, and the treatment performed.

There are only a few epidemiological studies of patients with DM [6–23]; many of them are limited to cross-sectional [7, 9, 11, 16, 17] or retrospective studies [6, 12, 14, 15, 18, 20, 22] with a small [13, 18, 23] or heterogeneous sample of patients with DM [9, 11, 13, 18, 23]. Of these, only five studies specifically evaluated a cohort of Brazilian patients [6, 7, 14, 15, 17]. A list of previous epidemiological studies in patients with DM and a comparison with our findings is summarized in Additional file 1: Table S1 and discussed in the following paragraphs.

In contrast to the articles mentioned above, the present study analyzed a longitudinal database, thus reducing methodological biases. Strict inclusion and exclusion criteria were applied to eliminate possible confounding factors. Finally, to characterize myositis-specific and myositis-associated autoantibodies, a commercial kit was used.

Patients with DM usually present skin involvement followed by muscle weakness [28]. Regarding the classic cutaneous signs, heliotrope and Gottron's papules/sign are the most closely linked to DM [6, 7, 12, 14, 15, 17, 19, 20]. Likewise, our study revealed that the most common skin finding was Gottron's papules/sign.

Other skin abnormalities, such as calcinosis, are associated with impaired quality of life due to ulcerations and secondary infections, which develop in approximately 30% of adult patients with DM [29]. In contrast to the available literature, this manifestation was much lower (4.4%) in our sample, possibly due to early diagnosis and aggressive initial treatment.

Excluding the primary involvement sites of DM, the lungs are the most affected sites, and manifestations such as ILD are associated with higher morbidity and mortality [7, 14, 17, 30]. A meta-analysis by Sun et al. [29] showed a prevalence of 41% of ILD in patients with DM, predominantly among Asians. In the present study, 37.4% of the patients had pulmonary involvement and 35.2% had ILD.

Gastrointestinal manifestations are well known in DM, and the main symptom is oropharyngeal dysphagia. The severe form of dysphagia has a wide prevalence, ranging from 10 to 73% [31]. Corroborating data from the literature, the prevalence of dysphagia in our study was 73.6%.

The treatment approach should be individualized based on the severity of clinical presentation, disease duration, presence of extramuscular characteristics, prior therapies, and contraindications to specific agents [32, 33]. The therapeutic regimen implemented in our service initially comprised the administration of oral glucocorticoids at a dose of 0.5–1.0 mg/kg/day. Subsequently, immunosuppressants and immunomodulators were indicated for the most severe cases. In addition to these medications, other early interventions (during the first year) were performed using IVMP, IVIg, or both.

Previous studies have shown an increase in patient survival or higher rates of complete clinical response when glucocorticoids were administered earlier and at high doses [32, 33]. In addition, an early approach to targeted treatment with IVMP and/or IVIg was associated with a potential reduction in long-term muscle disability and better outcomes (complete clinical response and discontinuation of corticosteroids) [34, 35].
It is important to emphasize that adjuvant therapies with immunomodulators and immunosuppressants, such as leflunomide, seem to be safe and effective for cases of refractory DM with primary cutaneous activity [36]. Due to the established therapeutic regimen, it was possible to verify at the last visit, that approximately half of the patients developed complete clinical response and only 27.3% still showed disease activity.

Infections are associated with increased mortality in patients with DM, leading to death in 9–30% of cases. A wide variety of microorganisms may be responsible for pyogenic and opportunistic infections in DM. The most common are mycobacteria and fungi (Pneumocystis jirovecii, Candida spp.) [37]. The rate of serious infections in DM patients is 11.1 cases/100 patients/year; The
main cause is aspiration pneumonia, followed by opportunistic infections [38].

During follow-up, there were 92 episodes of severe infection, the most frequent being community-acquired pneumonia, followed by herpes zoster, tuberculosis, COVID-19, and other infections.

The prevalence of systemic arterial hypertension and diabetes mellitus was high at the onset of myositis and tended to increase after the diagnosis of myositis [39, 40]. Comorbidities, such as systemic arterial hypertension, diabetes mellitus, and acute myocardial infarction, were present in 46.2%, 19.8%, and 4.4% of patients, respectively. The high prevalence of systemic arterial hypertension in the present study was only observed in previous studies that presented heterogeneous patient samples (with different inflammatory myopathies) [40].

Malignant neoplasms have been associated with DM, including gynecological ones, particularly ovarian carcinoma [23]. Compared to the literature, this study revealed a higher occurrence of cancer; the principal primary site was the female breast [12, 23]. This finding could be explained by the fact that these articles only considered cases of cancer with an interval no more than three years before or after the DM diagnosis. In addition, the follow-up periods in these studies were shorter than those presented herein (44 months).

This study also assessed the correlation between autoantibodies and patient characteristics and outcomes. The main autoantibodies were observed at a similar frequency in comparison with other studies [6, 7, 9, 12–14, 18, 20–23]: anti-Mi-2 (11%), anti-MDA-5 (11%), anti-Jo-1 (11%), and anti-Ro-52 (28.6%). The different frequencies of autoantibodies among studies may be explained by the small and heterogeneous samples of patients and distinct assessment methods. A strength of our study is that we evaluated a homogeneous population and used an accurate autoantibody analysis assay.

According to the literature, anti-Jo-1 is associated with joint involvement, “mechanic’s hands”, and ILD [15]; anti-Mi-2 is associated with cutaneous manifestations, low frequency of pulmonary involvement, low glucocorticoid requirement, and high DM remission rate [14]; and anti-MDA-5 is associated with different forms of skin involvement, especially skin ulcers and others resembling antisynthetase syndrome [6, 7, 18, 19]. Similarly, the associations found were anti-tRNA synthetases with ILD, “mechanic’s hands”, and anti-Ro52, with a negative association with “V”-neck and “shawl” signs. Anti-MDA-5 were associated with male gender, digital ulcers, vasculitis, arthritis, anti-Ro-52, and active disease. Anti-Ro-52 were associated with “mechanics’ hands”, arthritis, rapidly-progressive ILD, anti-tRNA synthetases, and

Table 5  Autoantibodies and their association with specific sets of clinical, imaging, and laboratory features of dermatomyositis using a univariate binary logistic regression

| Characteristics                  | ANA (n = 62) | Anti-ARS (n = 13) | Anti-MDA-5 (n = 10) | Anti-Ro-52 (n = 26) |
|----------------------------------|-------------|-------------------|--------------------|---------------------|
|                                  | P           | OR (95% CI)       | P                  | OR (95% CI)         | P                   |
| Male gender                      | NS          | NS                |                    |                     | 0.025               | 4.90 (1.22–19.69)   |
| Heliotrope rash                  | 0.043       | 3.63 (1.04–12.64) | NS                 |                     | NS                  | NS                  |
| “V”-neck sign                    | NS          | <0.001            | 0.07 (0.02–0.28)   | NS                  | NS                  | NS                  |
| “Shawl” sign                     | NS          | 0.021             | 0.22 (0.06–0.79)   | NS                  | NS                  | NS                  |
| Raynaud’s phenomenon             | 0.040       | 2.58 (1.05–6.39)  | NS                 | NS                  | NS                  | NS                  |
| “Mechanics’ hands”               | NS          | 0.010             | 5.30 (1.49–18.90)  | NS                  | NS                  | 0.011               | 4.30 (1.41–13.13)   |
| Digital ulcers                   | NS          | NS                |                    |                     | NS                  | NS                  |
| Vasculitis                       | NS          | NS                |                    |                     | NS                  | NS                  |
| Arthritis                        | NS          | NS                |                    |                     | NS                  | NS                  |
| ILD                              | NS          | 0.011             | 5.38 (1.47–19.72)  | NS                  | NS                  |
| RP-ILD                           | NS          | NS                |                    | 0.034               | 4.78 (1.12–20.36)   |
| Anti-ARS                          | NS          | –                 | –                  |                     | 0.035               | 3.82 (1.10–13.28)   |
| Anti-MDA-5                       | NS          | NS                |                    | –                   | 0.035               | 3.82 (1.10–13.28)   |
| Anti-Ro-52                       | NS          | 0.035             | 3.82 (1.10–13.28)  | 0.021               | 5.53 (1.29–23.68)   |
| Active disease                    | NS          | NS                |                    | 0.013               | 6.11 (1.47–25.43)   |

No association was found between anti-Mi-2 and the several clinical, imaging, and laboratory characteristics assessed.

The following characteristics had no statistical association with specific autoantibodies and therefore were not included in the table: age at diagnosis (years), ethnicity, fever/weight loss, Gottron’s sign or papules, calcinosis, muscle weakness, dysphagia, maximum CPK, ANA, anti-Mi-2, severe infections, neoplasia, complete clinical response, disease remission, and death.

ANA, antinuclear antibody; ARS, anti-tRNA synthetase; CPK, creatine phosphokinase; ILD, interstitial lung disease; NS, not significant; P, two-tailed P-value; RP, rapidly progressive.
anti-MDA-5. Contrary to other studies, no correlation was observed between anti-Mi-2 and cutaneous manifestations, frequency of pulmonary involvement, glucocorticoid use, or disease remission. As limitations of this study, osteoporosis, opportunistic infections, disability, and quality of life were not evaluated. Another limitation was related to Muscle strength graded classification, as we used MRC instead of MMT-8.

Conclusions
The present study demonstrated the clinical, laboratory, and outcome characteristics of Brazilians with a definitive diagnosis of DM and explored the associations between myositis-specific and myositis-associated DM autoantibodies in this homogeneous population. Therefore, our thorough data allowed better characterization of DM in terms of clinical manifestations, evolution, and prognosis in DM.

Abbreviations
ACR: American College of Rheumatology; ALT: Aminotransferase alanine; ANA: Antinuclear antibody; AST: Aminotransferase aspartate; CPK: Creatine phosphokinase; EULAR: European League Against Rheumatism; IQR: Interquartile range; ILD: Incipient interstitial lung disease; IVMP: Intravenous methylprednisolone; IVlg: Intravenous immunoglobulin; LDH: Lactic dehydrogenase; MRC: Medical Research Council.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s42358-022-00276-x.

Additional file 1. Complementary Table 1. Epidemiological studies in patients with dermatomyositis.

Acknowledgements
Maria Aurora Gomes da Silva for assistance and support in all laboratory processing.

Author contributions
NCCT, LSH, IBPB, FHCS and SKS have contributed equally to the writing and reviewing of the manuscript. All authors read and approved the final manuscript.

Funding
This study was support by Brazilian Society of Rheumatology; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP): #2021/04892-0, #2019/11367-9, and #2019/11776-6; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq): #303379/2018-9.

Availability of data and materials
Not applicable.

Declarations
Ethical approval and consent to participate
This study was approved by the local ethics committee (CAAE 68523717.1.0000.0068), and all participants signed the term free and informed consent.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no conflicts of interest.

Author details
1. Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3º Andar, sala 3184 - Cerqueira César, Sao Paulo, SP CEP: 01246-903, Brazil. 2. Division of Rheumatology, Faculdade de Medicina, Universidade Potiguar (UnP), Natal, RN, Brazil. 3. Division of Rheumatology, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Received: 20 June 2022 Accepted: 29 October 2022
Published online: 12 November 2022

References
1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47.
2. Sena P, Gianatti A, Gambini D. Dermatomyositis: clinicopathological correlations. G Ital Dermatol Venerol. 2018;153:256–64.
3. Shinjo SK. Miopatias autoimunares sistêmicas. Rev Paul Reumatol. 2017;16:6–11.
4. Bolko L, Gitaux C, Allenbach Y. Dermatomyositis nouvelles anticorps, nouvelle classification. Médecine/Sciences. 2019;35:18–23.
5. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.
6. Olivo Palle PA, Hoff LS, Borges IBP, et al. Characterization of patients with dermatomyositis according to anti-melanoma differentiation-associated gene-5 autoantibodies in centers of 3 Latin American countries. J Clin Rheumatol. 2021;27:e444–8.
7. Borges IBP, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis. An Bras Dermatol. 2018;93:517–23.
8. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor-1y antibodies in adults with dermatomyositis. Arthritis Rheum. 2013;65:2954–62.
9. Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36:935–43.
10. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28:796–803.
11. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis. Arch Dermatol. 2011;147:391–8.
12. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1y antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449–55.
13. Komura K, Fujimoto M, Matsuhashi T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40:215–20.
14. dos Passos Carvalho MIC, Shinjo SK. Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis. Adv Rheumatol. 2019;59:27.
15. de Andrade VP, de Souza FHC, Behrens Pinto GL, et al. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol. 2021;61:12.
16. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496–502.
19. Hall JC, Casciola-Rosen L, Samedy L-A, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307–15.

20. Masiak A, Kutzcycka J, Czuzszyńska Z, et al. Clinical characteristics of patients with anti-TIF1-γ antibodies. Rheumatology. 2016;1:14–8.

21. Albaia J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69:1771–6.

22. Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68:689–94.

23. Hoshino K, Muro Y, Sugiiura K, et al. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726–33.

24. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:19551964.

25. Songheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.

26. Compton A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: nerve injuries research committee. His Majesty’s Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous. Brain. 2010;133:2832844.

27. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner H, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52(9):2607–15.

28. Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010;146:26–30.

29. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.

30. de Souza FHC, Barros TBM, Levy-Neto M, et al. Adult dermatomyositis: experience of Brazilian tertiary care center. Rev Bras Reumatol. 2012;52:897–902.

31. Airo A, Kautainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol. 2006;25:234–9.

32. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.

33. de Souza JM, Hoff LS, Shinjo SK. Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies. Rheumatol Int. 2019;39:1201–12.

34. Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology. 2022;61:1579–88.

35. de Souza RC, de Souza FHC, Miossi R, et al. Efficacy and safety of leflunomide as an adjunct drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. 2017;35:1011–3.

36. de Souza FHC, de Araújo DE, Vilêsa V, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol. 2019;59:6.

37. de Souza HFC, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol. 2014;32:82–7.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.